Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era

Urology

Volumn 70, Issue 5, 2007, Pages 950-955

  Desireddi, Naresh V ^a   Roehl, Kimberly A ^b   Loeb, Stacy ^c   Yu, Xiaoying ^a   Griffin, Christopher R ^a   Kundu, Shilajit K ^a   Han, Misop ^d   Catalona, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 36549046578     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.06.1119     Document Type: Article

References (27)

1. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948-954
2. Loeb S., Gonzalez C.M., Roehl K.A., et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 175 (2006) 902-906
3. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
4. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 277 (1997) 1445-1451
5. Han M., Partin A.W., Piantadosi S., et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166 (2001) 416-419
6. Jhaveri F.M., Klein E.A., Kupelian P.A., et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 17 (1999) 3167-3172
7. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910-914
8. Ung J.O., Richie J.P., Chen M.H., et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60 (2002) 458-463
9. National Cancer Institute. SEER Cancer Statistics Review 1975-2003. Bethesda, National Cancer Institute.
10. Walsh P.C., and Donker P.J. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128 (1982) 492-497
11. Jemal A., Ward E., Wu X., et al. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14 (2005) 590-595
12. McCarthy J.F., and Catalona W.J. Nerve-sparing radical retropubic prostatectomy. In: Marshall F.F. (Ed). Textbook of Operative Urology (1996), WB Saunders, Philadelphia 537-544
13. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
14. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 23 (1992) 273-279
15. Catalona W.J., and Smith D.S. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152 (1994) 1837-1842
16. Stephenson R.A. Prostate cancer trends in the era of prostate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 29 (2002) 173-181
17. Kundu S.D., Roehl K.A., Eggener S.E., et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 172 (2004) 2227-2231
18. Jang T.L., Han M., Roehl K.A., et al. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 67 (2006) 343-348
19. Roberts R.O., Bergstralh E.J., Katusic S.K., et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 161 (1999) 529-533
20. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
21. Ohori M., Wheeler T.M., Dunn J.K., et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152 (1994) 1714-1720
22. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
23. Kopec J.A., Goel V., Bunting P.S., et al. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 174 (2005) 495-499
24. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417-424
25. Humphrey P.A., Keetch D.W., Smith D.S., et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 155 (1996) 816-820
26. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 (2005) 1248-1253
27. Smith E.B., Frierson Jr. H.F., Mills S.E., et al. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?. Cancer 94 (2002) 2282-2287